April 10 (Reuters) - Keros Therapeutics ( KROS ) said on

Thursday its board had authorized a stockholder rights plan,

also known as a "poison pill", in response to rapid

accumulations of the company's stock by some investors.

The company also said it had launched a process to evaluate

strategic alternatives, including a possible sale of the

company.